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Introduction: In spite of undebated benefits of the use of aspirin for the prevention 
of cardiovascular disease (CVD), due to the side effects of aspirin, which are  mainly 
gastrointestinal bleeding and hemorrhagic stroke, its use in primary prevention is 
still contentious. Stroke is one of the important CVD events which is responsible for 
a major cause of death among Iranian women. For the first time, the cost-
effectiveness and cost-utility of the use of aspirin for the primary prevention of 
stroke among women in Iran with an average risk of CVD was evaluated in this 
study.  
Methods and Results: The incremental cost-effectiveness ratios (ICERs) were 
estimated using a semi-Markov model in which the cost-effectiveness of the use of 
80mg aspirin  was compared to control group The adopted time horizon was life-
long and the analysis was performed from the payer's perspective. The target 
population was a hypothetical cohort of 55-year women with a 10-year CVD risk of 
15% and no history of previous CVD. A loss of 0.4 QALYs (Quality-Adjusted-Life-
Years) and 0.58 LYG (Life-Years-Gained) with an extra cost of 6,150,946 Rials per 
patient were estimated in this study,. The implemented one-way and probabilistic 
sensitivity analyses represented the robustness of the model.  
Conclusion: The use of aspirin for the primary prevention of stroke among women 
with an average CVD risk, seems not to be a cost-effective intervention in Iran. 
However the cost-effectiveness of the use of aspirin for other CVD including 
myocardial infarction (MI) needs to be taken into account in decision making. 
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